Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present INDIVIOR PLC (OTC: INVVY).

Full DD Report for INVVY

You must become a subscriber to view this report.

Recent News from (OTC: INVVY)

Indivior (INVVY) Trading Update - Slideshow
The following slide deck was published by INDIVIOR PLC ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: December, 18 2018 13:19
60 Minutes to air piece on opioid drugmakers and distributors Sunday
CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden...
Source: SeekingAlpha
Date: December, 14 2018 13:50
Court of Appeals for the Federal Circuit Declines to Immediately Issue Mandate After Preliminary Injunction Ruling
SLOUGH, England, Dec. 12, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied Dr. Reddy's Laboratories (DRL's) motion to immediately issue the mandate following the CAFC's ...
Source: PR Newswire
Date: December, 12 2018 08:00
Indivior to Host Conference Call on December 18th; Previously-Scheduled Capital Markets Day to be Held in February 2019
SLOUGH, England , Nov. 27, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that in light of the recent decision by the Court of Appeals for the Federal Circuit (CAFC) vacating the preliminary injunction against Dr. Reddy's Laboratories (DRL) the...
Source: PR Newswire
Date: November, 27 2018 08:00
Indivior +4.2% after Canada approves Sublocade for opioid use disorder
Indivior ( OTCPK:INVVY )  rises 4.2%  after Health Canada approves Sublocade buprenorphine extended-release injection for the managing moderate to severe opioid use disorder. More news on: INDIVIOR PLC ADR, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: November, 23 2018 10:42
Indivior Announces Health Canada Approval of SUBLOCADETM (Buprenorphine Extended-Release) Injection for Patients with Moderate to Severe Opioid Use Disorder
SUBLOCADE is the first and only once-monthly injectable buprenorphine formulation approved in Canada for the management of moderate to severe opioid use disorder SLOUGH, England and RICHMOND, Va. , Nov. 23, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today ...
Source: PR Newswire
Date: November, 23 2018 09:56
Indivior -12% after court lifts injunction against Suboxone generic
Indivior PLC ( OTCPK:INVVY ) sinks 12%  after a U.S. appeals court vacates a preliminary injunction that had prevented Dr. Reddy's Laboratories ( RDY +0.7% ) from selling a generic version of Suboxone, Indivior's product that used to treat opioid dependence. More news on: INDIVIO...
Source: SeekingAlpha
Date: November, 21 2018 11:44
Court of Appeals for the Federal Circuit Lifts Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film
SLOUGH, England , Nov. 21, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) vacated the preliminary injunction (PI) previously granted against Dr. Reddy's Laboratories (DRL) by...
Source: PR Newswire
Date: November, 21 2018 09:30
PERSERIS(TM), the First Once-Monthly Risperidone-Containing Subcutaneous Long-Acting Injectable, Now Available in the U.S. for the Treatment of Schizophrenia in Adults
SLOUGH, England and RICHMOND, Va. , Nov. 19, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that PERSERIS ™ (risperidone) for extended-release injectable suspension is now available in the United States . PERSERIS is approved by the U.S. Food and Drug ...
Source: PR Newswire
Date: November, 19 2018 08:06
Indivior Announces Upcoming Investor Events
SLOUGH, United Kingdom and RICHMOND, Va. , Nov. 6, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the following upcoming investor events: Stifel 2018 Healthcare Conference, New York City : On Tuesday, November 13 th from 9:30 a.m. to 10:10 a.m. (loca...
Source: PR Newswire
Date: November, 06 2018 08:00


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on INVVY.



Indivior began with the goal of addressing the lack of treatment for the worldwide problem of addiction. Even though it was an area of business that was unproven, we believed we could make a measurable difference in the lives of patients all over the world. Through a grassroots effort, we ve partnered with and educated governments, policy makers, payers, and heathcare professionals about diseases of addiction and the value of alternative treatment options including office based treatment . We ve also worked diligently and strategically to identify and address the unmet treatment needs of patients. By creating a marketplace environment of increased acceptance, we have provided an estimated million patients effective treatment options.


Contact Information



Current Share Structure


    Daily Technical Chart for (OTC: INVVY)

    Daily Technical Chart for (OTC: INVVY)

    Stay tuned for daily updates and more on (OTC: INVVY)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: INVVY)

    Do your DD and if you choose, be ready to go!


    The Research: All source information contained in this email is from the public sources mentioned below.



    Thank you

    DD Report



    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in INVVY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of INVVY and does not buy, sell, or trade any shares of INVVY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: